Events
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
-
-
Strong, durable responses to selpercatinib in RET-driven medullary thyroid cancer
Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the…
Immune protein IL-17A responsible for lethal side effects of gastric cancer
Gastric cancer, one of the leading causes of cancer-associated mortality worldwide, is renowned for its…
New data on emerging treatments for liver cancer raise hope for advanced disease patients
New treatment options for people with advanced or unresectable hepatocellular carcinoma (HCC) may now be…
ESMO 2020: Research breakthrough offers new hope for high risk patients with HR+ breast cancer
- ESMO 2020: First new drug in years reduces recurrence in high-risk hormone receptor positive early breast cancer
- ESMO 2020: Sacituzumab govitecan-hziy extends survival in phase 3 ASCENT study of metastatic triple-negative breast cancer
- Spotting breast cancer’s spread to the brain before symptoms start could improve survival
ASM Report from the ANZBCTG
2016 Joint COSA/ANZBCTG Annual Scientific Meeting The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) recently held a joint…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.